lilly retatrutide trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v A new clinical trial from

Ozempic Distinction Both drugs utilize the active ingredient semaglutide, but their dosing schedules differ significantly

Learning to eat "logically" rather than "emotionally" is a skill that takes time to develop

Physical changes extend beyond weight loss

Our goal is to provide compassionate, evidence-based care that addresses the underlying factors contributing to weight gain while helping patients build sustainable, healthy habits

These findings suggest that GLP-1 benefits in weight and glucose control outweigh renal risks when therapy is appropriately managed

It is the same medication, but instead of a weekly injection, it is taken as a once daily tablet